Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma

Michael R Stephens; Maria S Asdourian; Ted V Jacoby; Nishi Shah; Leah L Thompson; Tracey Otto; Yevgeniy R Semenov; Kerry L Reynolds; Ryan J Sullivan; Ruth K Foreman; Steven T Chen

doi:10.1016/j.jaad.2023.01.040

Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma

J Am Acad Dermatol. 2023 Jul;89(1):140-142. doi: 10.1016/j.jaad.2023.01.040. Epub 2023 Feb 15.

Authors

Affiliations

¹ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Combined Dermatology Residency, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
³ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu, Hawaii.
⁴ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Virginia Commonwealth University School of Medicine, Richmond, Virginia.
⁵ Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
⁶ Harvard Medical School, Boston, Massachusetts; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
⁷ Harvard Medical School, Boston, Massachusetts; Dermatopathology Service, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
⁸ Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: stchen@partners.org.

No abstract available

Keywords: cutaneous immune-related adverse event; dermatologic toxicity; immune checkpoint inhibitor; immunotherapy; melanoma; prognostic biomarkers; tumor-infiltrating lymphocytes.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Biomarkers, Tumor
Humans
Immune Checkpoint Inhibitors* / adverse effects
Immunotherapy
Lymphocytes, Tumor-Infiltrating
Melanoma* / drug therapy

Substances

Immune Checkpoint Inhibitors
Biomarkers
Biomarkers, Tumor

Publication types

MeSH terms

Substances

Grants and funding